Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Delayed Quote. Delayed  - 02/23 08:03:34 am
68.375 EUR   +0.31%
02/23 UCB FULL YEAR R : UCB demonstrates continued top and …
02/16 UCB : Transparency notification
02/09 UCB : Transparency notifications
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
02/17/2017 02/20/2017 02/21/2017 02/22/2017 02/23/2017 Date
68.035(c) 67.968(c) 67.81(c) 68.166(c) 68.375 Last
746 0 0 0 0 Volume
+0.78% -0.10% -0.23% +0.52% +0.31% Change
More quotes
Financials (€)
Sales 2016 4 069 M
EBIT 2016 754 M
Net income 2016 476 M
Debt 2016 898 M
Yield 2016 1,78%
Sales 2017 4 336 M
EBIT 2017 898 M
Net income 2017 579 M
Debt 2017 552 M
Yield 2017 1,95%
P/E ratio 2016 25,84
P/E ratio 2017 21,19
EV / Sales2016 3,50x
EV / Sales2017 3,20x
Capitalization 13 333 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
02/23 UCB FULL YEAR REPORT 2016 : UCB demonstrates continued top and …
02/16 UCB : Transparency notification
02/09 UCB : Transparency notifications
02/08 UCB : Transparency notifications
01/25 UCB : Transparency notifications
01/19 UCB : files BRIVIACT® (brivaracetam) CV in the U.S. as …
01/19 UCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy &h..
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency Notification
More news
Sector news : Pharmaceuticals - NEC
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
02/23DJPURETECH HEALTH : Appoints Atul Pande as Chief Medical Officer
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
02/23DJBAYER : CEO Still Upbeat on Deal -- WSJ
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 77,0 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA11.07%14 075
JOHNSON & JOHNSON3.86%325 158
ROCHE HOLDING LTD.5.98%210 992
PFIZER INC.3.51%203 836
NOVARTIS AG3.51%202 566
MERCK & CO., INC.11.23%180 014
More Results